Cladribine - Johnson and Johnson/Merck Serono

Drug Profile

Cladribine - Johnson and Johnson/Merck Serono

Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Mavenclad; Movectro; Mylinax; N-l-Leucyl-doxorubicin; RWJ 26251

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scripps Clinic
  • Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
  • Class Antineoplastics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis; Leukaemia; Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 09 Apr 2018 Launched for Multiple sclerosis (Monotherapy) in Canada (PO) before April 2018
  • 09 Apr 2018 Launched for Multiple sclerosis in Scotland, Luxembourg, Denmark, Argentina, Norway, Israel (PO) before April 2018
  • 09 Apr 2018 Registered for Multiple sclerosis in United Arab Emirates (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top